1. HBW Insight
  2. >>Ingredients & Safety

Second Wind For OTC Monograph User Fee Legislation In House Hearing

 
• By Malcolm Spicer

House Health Subcommittee's “Modernizing FDA’s Regulation of Over-the-Counter Drugs” hearing Sept. 13 will "examine draft legislation to establish" a user fee program to support FDA's work on evaluating proposals for additions or changes to its nonprescription drug monographs.

Chances this year for legislation on reforming FDA's OTC drug monograph program and creating a user fee to support it could be revived as a House subcommittee expects to have a draft bill ready for a hearing on Sept. 13.

The Energy and Commerce Committee's Health Subcommittee's “Modernizing FDA’s Regulation of Over-the-Counter Drugs” hearing will "examine draft legislation to establish"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By David Ridley

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 
• By Malcolm Spicer

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

More from HBW Insight

Paying User Fees Not A Priority For Many OTC Monograph Drug Firms, First Arrears List Shows

 
• By Malcolm Spicer

The 1,383 entries on OMUFA arrears list for facility registrations from FY2021 through FY2025 on FDA’s list exceeds its estimate of 1,134 entities subject to the fee for FY2025.

IBA Names Ooka Interim CEO; P&G, Sally Beauty Appoint Board Members – Appointments Roundup

The Independent Beauty Association announces CEO Don Frey will retire July 1 and will be replaced as interim CEO by Akemi Ooka, VP of global supply chain and sustainability resources.

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By Tom Gallen

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.